Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
On Tuesday, Johnson & Johnson (NYSE:JNJ) agreed to acquire V-Wave for an upfront payment of $600 million, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.
周二，强生公司（纽约证券交易所代码：JNJ）同意以6亿美元的预付款收购V-Wave，并有可能额外支付高达约11亿美元的监管和商业里程碑款项。
V-Wave is a privately held medical device company focused on developing heart failure and cardiovascular disease treatment options.
V-Wave 是一家私营医疗器械公司，专注于开发心力衰竭和心血管疾病治疗方案。
V-Wave will join Johnson & Johnson as part of Johnson & Johnson MedTech.
V-Wave将作为强生医疗科技公司的一部分加入强生公司。
Also Read: Johnson & Johnson Nears Approval for $6.5B Long Standing Talc Settlement.
另请阅读：强生公司65亿美元的长期滑石粉和解协议即将获得批准。
The planned acquisition of V-Wave will extend Johnson & Johnson MedTech's position in addressing cardiovascular disease.
计划收购V-Wave将扩大强生医疗科技在解决心血管疾病方面的地位。
It will further accelerate its shift into high-growth and high-opportunity markets.
它将进一步加快向高增长和高机会市场的转移。
V-Wave's Ventura Interatrial Shunt (IAS) is an implantable device designed to decrease elevated left atrial pressure in congestive heart failure by creating a shunt between the left and right atrium. This reduces cardiovascular events and heart failure hospitalizations.
V-Wave 的 Ventura 心房分流器 (IAS) 是一种植入式设备，旨在通过在左心房和右心房之间形成分流来降低充血性心力衰竭患者左心房压升高。这减少了心血管事件和心力衰竭住院人数。
The transaction is expected to close before the end of 2024.
该交易预计将在2024年底之前完成。
Johnson & Johnson expects the transaction to dilute adjusted EPS by approximately $0.24 in 2024 and approximately $0.06 in 2025.
强生公司预计，该交易将在2024年使调整后的每股收益稀释约0.24美元，在2025年使调整后的每股收益减少约0.06美元。
On Tuesday, the FDA also approved Johnson & Johnson's Rybrevant (amivantamab) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
周二，美国食品药品管理局还批准了强生公司的Rybrevant（amivantamab）加Lazcluze（lazertinib），用于一线治疗具有表皮生长因子受体（EGFR）19外显子缺失或21外显子 L858R 替代突变的局部晚期或转移性非小细胞肺癌（NSCLC）的成年患者。
With this milestone, Rybrevant plus Lazcluze becomes the first and only multitargeted, chemotherapy-free combination regimen with demonstrated superiority versus AstraZeneca Plc's (NASDAQ:AZN) Tagrisso (osimertinib) approved for the first-line treatment of patients with EGFR-mutated NSCLC.
凭借这一里程碑，Rybrevant加Lazcluze成为第一个也是唯一一种多靶向、不含化疗的联合方案，与获准用于表皮生长因子突变非小细胞肺癌患者一线治疗的阿斯利康公司（纳斯达克股票代码：AZN）Tagrisso（奥美替尼）相比，具有显著优势。
The FDA approval is based on results from the Phase 3 MARIPOSA study, which reduced the risk of disease progression or death by 30% compared to osimertinib (median progression-free survival 23.7 months versus 16.6 months).
美国食品药品管理局的批准基于MARIPOSA的3期研究结果，与奥美替尼相比，该研究将疾病进展或死亡的风险降低了30％（无进展存活期中位数为23.7个月对比16.6个月）。
The median duration of response was nine months longer with Rybrevant plus Lazcluze versus osimertinib (25.8 months versus 16.7 months), a secondary endpoint of the study.
与奥美替尼相比，Rybrevant加Lazcluze的中位缓解持续时间延长了九个月（25.8个月对16.7个月），后者是该研究的次要终点。
Price Action: JNJ stock is up 0.5% at $160.43 at last check Tuesday.
价格走势：在周二的最后一次检查中，JNJ股价上涨0.5％，至160.43美元。
- Eli Lilly's Famed Obesity/Diabetes Treatment Tirzepatide Shows Potential To Cut Risk Of Developing Diabetes, Sustained Weight Loss Over 3 Years.
- 礼来公司著名的肥胖/糖尿病治疗药物替西帕肽显示出降低患糖尿病风险的潜力，在3年内持续减肥。
Photo: Shutterstock
照片：Shutterstock